SG11201706583PA - Anti-pvrig antibodies and methods of use - Google Patents

Anti-pvrig antibodies and methods of use

Info

Publication number
SG11201706583PA
SG11201706583PA SG11201706583PA SG11201706583PA SG11201706583PA SG 11201706583P A SG11201706583P A SG 11201706583PA SG 11201706583P A SG11201706583P A SG 11201706583PA SG 11201706583P A SG11201706583P A SG 11201706583PA SG 11201706583P A SG11201706583P A SG 11201706583PA
Authority
SG
Singapore
Prior art keywords
methods
pvrig antibodies
pvrig
antibodies
Prior art date
Application number
SG11201706583PA
Inventor
Mark White
Sandeep Kumar
Christopher Chan
Spencer Liang
Lance Stapleton
Andrew W Drake
Yosi Gozlan
Iian Vaknin
Shirley Sameah-Greenwald
Liat Dassa
Zohar Tiran
Gad S Cojocaru
Leonard Presta
Richard Theolis
Original Assignee
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55453315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201706583P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Compugen Ltd filed Critical Compugen Ltd
Publication of SG11201706583PA publication Critical patent/SG11201706583PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
SG11201706583PA 2015-02-19 2016-02-19 Anti-pvrig antibodies and methods of use SG11201706583PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562118208P 2015-02-19 2015-02-19
US201562141120P 2015-03-31 2015-03-31
US201562235823P 2015-10-01 2015-10-01
PCT/US2016/018809 WO2016134333A1 (en) 2015-02-19 2016-02-19 Anti-pvrig antibodies and methods of use

Publications (1)

Publication Number Publication Date
SG11201706583PA true SG11201706583PA (en) 2017-09-28

Family

ID=55453315

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201706583PA SG11201706583PA (en) 2015-02-19 2016-02-19 Anti-pvrig antibodies and methods of use

Country Status (23)

Country Link
US (7) US10227408B2 (en)
EP (4) EP3653221B1 (en)
JP (2) JP7115856B2 (en)
KR (1) KR102669294B1 (en)
CN (2) CN115350275A (en)
AU (3) AU2016219835B2 (en)
CA (1) CA2976926A1 (en)
CY (2) CY1122970T1 (en)
DK (3) DK3653221T3 (en)
ES (3) ES2929293T3 (en)
HK (2) HK1247569A1 (en)
HR (3) HRP20221284T1 (en)
HU (3) HUE049032T2 (en)
IL (2) IL254039B2 (en)
LT (3) LT3258951T (en)
MX (2) MX2017010667A (en)
PL (3) PL3295951T3 (en)
PT (3) PT3653221T (en)
RU (2) RU2020128686A (en)
SG (1) SG11201706583PA (en)
SI (2) SI3295951T1 (en)
WO (1) WO2016134333A1 (en)
ZA (1) ZA201706323B (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130058957A1 (en) * 2010-02-23 2013-03-07 The University Of Tokyo Dendritic cell immunoreceptor agonist
DK3083671T3 (en) 2013-12-20 2020-12-07 Hutchinson Fred Cancer Res LABELED CHIMARY EFFECTOR MOLECULES AND RECEPTORS THEREOF
EP3978929A1 (en) 2015-02-19 2022-04-06 Compugen Ltd. Pvrig polypeptides and methods of treatment
PT3653221T (en) 2015-02-19 2022-11-08 Compugen Ltd Anti-pvrig antibodies and methods of use
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
WO2016196389A1 (en) * 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
KR20180054639A (en) * 2015-08-28 2018-05-24 알렉터 엘엘씨 Anti-SIGLEC-7 Antibodies and Methods of Use Thereof
CA2997179A1 (en) * 2015-09-02 2017-03-09 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
PT3347379T (en) * 2016-08-17 2020-02-18 Compugen Ltd Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
BR112019005633A8 (en) 2016-09-23 2023-04-11 Hutchinson Fred Cancer Res SPECIFIC TCRS FOR HISTOCOMPATIBILITY (H) MINOR HA-1 ANTIGEN AND USES THEREOF
EA201992131A1 (en) 2017-03-15 2020-02-06 Фред Хатчинсон Кэнсер Рисерч Сентер HIGH-AFFINE SPECIFIC TO MAGE-A1 TCR AND THEIR APPLICATION
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
US11576933B2 (en) 2017-05-24 2023-02-14 Effector Therapeutics Inc. Compositions and methods for an improved antitumor immune response
JP7348072B2 (en) * 2017-06-01 2023-09-20 コンピュジェン リミテッド Triple combination antibody therapy
US11161897B2 (en) 2017-07-17 2021-11-02 Janssen Biotech, Inc. Antigen binding regions against fibronectin type III domains and methods of using the same
WO2019051135A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center Methods for improving adoptive cell therapy
AU2018327229A1 (en) 2017-09-06 2020-02-27 Fred Hutchinson Cancer Center Strep-tag specific binding proteins and uses thereof
AU2018327225A1 (en) 2017-09-06 2020-02-27 Fred Hutchinson Cancer Center Strep-tag specific chimeric receptors and uses thereof
US10927180B2 (en) 2017-10-13 2021-02-23 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
WO2019109047A1 (en) 2017-12-01 2019-06-06 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
US11873341B2 (en) 2018-03-13 2024-01-16 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion
BR112020023380A2 (en) 2018-05-31 2021-02-09 Glyconex Inc. isolated antibody or antigen-binding fragment thereof, isolated polynucleotide, recombinant vector, host cell, method for producing an antibody or an agglutination fragment to the antigen thereof and for treating or detecting cancer, antibody conjugate, and pharmaceutical composition
SG11202011461TA (en) * 2018-06-01 2020-12-30 Compugen Ltd Anti-pvrig/anti-tigit bispecific antibodies and methods of use
MX2021000745A (en) * 2018-07-20 2021-03-26 Surface Oncology Inc Anti-cd112r compositions and methods.
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
WO2020041501A1 (en) 2018-08-22 2020-02-27 Fred Hutchinson Cancer Research Center Immunotherapy targeting kras or her2 antigens
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
KR20210091691A (en) * 2018-09-14 2021-07-22 킨드레드 바이오사이언시스, 인코포레이티드 Anti-IL4 Receptor Antibodies for Veterinary Use
WO2020068702A1 (en) 2018-09-24 2020-04-02 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
IL297931A (en) 2018-09-25 2023-01-01 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
MX2021005308A (en) 2018-11-09 2021-09-08 Fred Hutchinson Cancer Center Star T cell receptors specific for mesothelin and their use in immunotherapy.
PT3898668T (en) 2018-12-19 2023-12-06 Humabs Biomed Sa Antibodies that neutralize hepatitis b virus and uses thereof
AR117327A1 (en) 2018-12-20 2021-07-28 23Andme Inc ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THEM
US10836828B2 (en) 2019-02-06 2020-11-17 Pionyr Immunotherapeutics, Inc. Anti-TREM1 antibodies and related methods
BR112021015479A2 (en) * 2019-02-06 2021-12-28 Pionyr Immunotherapeutics Inc Anti-trem1 antibodies and related methods
EP3927727A1 (en) 2019-02-20 2021-12-29 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
CN113784978A (en) 2019-03-11 2021-12-10 弗雷德哈钦森癌症研究中心 High affinity WT 1T cell receptor and uses thereof
BR112022001575A2 (en) 2019-07-29 2022-04-19 Compugen Ltd Anti-pvrig antibody formulations and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US20220409661A1 (en) 2019-08-20 2022-12-29 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for wt-1
CA3152511A1 (en) 2019-08-29 2021-03-04 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
US20220378742A1 (en) 2019-11-04 2022-12-01 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
EP4058062A4 (en) * 2019-11-15 2023-11-08 Surface Oncology, Inc. Compositions and methods for immunotherapy
US20230057899A1 (en) 2019-12-05 2023-02-23 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
CA3170025A1 (en) * 2020-03-13 2021-09-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pvrig binding protein and its medical uses
BR112022026316A2 (en) 2020-06-24 2023-03-07 Vir Biotechnology Inc ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND THEIR USES
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
TW202216778A (en) * 2020-07-15 2022-05-01 美商安進公司 Tigit and cd112r blockade
JP2023542528A (en) 2020-09-24 2023-10-10 フレッド ハッチンソン キャンサー センター Immunotherapy targeting SOX2 antigen
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
TW202222841A (en) 2020-10-06 2022-06-16 福瑞德哈金森腫瘤研究中心 Compositions and methods for treating mage-a1-expressing disease
EP4232822A2 (en) * 2020-10-26 2023-08-30 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
CN112433055A (en) * 2020-11-04 2021-03-02 上海药明生物技术有限公司 Method for detecting biological activity of PVRIG antibody based on reporter gene method
CA3201767A1 (en) 2020-12-14 2022-06-23 Thomas M. Schmitt Compositions and methods for cellular immunotherapy
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
US20240092872A1 (en) 2021-01-26 2024-03-21 Vir Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
WO2022165275A2 (en) 2021-01-28 2022-08-04 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies
WO2022165266A1 (en) 2021-01-28 2022-08-04 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
EP4292611A1 (en) * 2021-02-09 2023-12-20 Shanghai Junshi Biosciences Co., Ltd. Anti-cd112r antibody and use thereof
CA3206413A1 (en) 2021-02-11 2022-08-18 Pinchas TSUKERMAN Antibodies against cd112r and uses thereof
CN115925917A (en) 2021-03-08 2023-04-07 合肥天港免疫药物有限公司 anti-PVRIG protein antibodies or antibody fragments and uses thereof
WO2022208353A1 (en) 2021-03-31 2022-10-06 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins and combinations thereof
WO2022258049A1 (en) * 2021-06-10 2022-12-15 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric pvrig
WO2023275621A1 (en) * 2021-07-01 2023-01-05 Compugen Ltd. Anti-tigit and anti-pvrig in monotherapy and combination treatments
WO2023285552A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
WO2023288281A2 (en) 2021-07-15 2023-01-19 Fred Hutchinson Cancer Center Chimeric polypeptides
AU2022320667A1 (en) 2021-07-30 2024-03-14 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-pvrig/anti-tigit bispecific antibody and application
TW202328195A (en) 2021-09-15 2023-07-16 大陸商江蘇恆瑞醫藥股份有限公司 Proteins that specifically bind to pd-1 and the pharmaceutical use thereof
TW202327649A (en) * 2021-09-15 2023-07-16 大陸商江蘇恆瑞醫藥股份有限公司 Pvrig/tigit binding proteins in combination with immune checkpoint inhibitors for the treatment of cancer
CA3231553A1 (en) 2021-09-15 2023-03-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
WO2023064958A1 (en) 2021-10-15 2023-04-20 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
CN114644711A (en) * 2022-03-07 2022-06-21 南京诺艾新生物技术有限公司 Recombinant anti-human PVRIG antibody and application thereof
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
CN116925222A (en) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 anti-PVRIG antibody, pharmaceutical composition and application thereof
CN116925233A (en) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 anti-TIGIT-anti-PVRIG bispecific antibody, pharmaceutical composition and use thereof
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023230439A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof
WO2023242247A1 (en) * 2022-06-14 2023-12-21 Ablynx Nv Immunoglobulin single variable domains targeting t cell receptor
WO2024026496A1 (en) 2022-07-28 2024-02-01 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
WO2024032700A1 (en) * 2022-08-10 2024-02-15 Beigene, Ltd. Anti-pvrig antibodies and methods of use
CN117957254A (en) * 2022-08-31 2024-04-30 石药集团巨石生物制药有限公司 Anti-PVRIG antibodies and uses thereof
WO2024098980A1 (en) * 2022-11-10 2024-05-16 Huahui Health Ltd. Anti-cd112r antibodies and use thereof
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
ATE135370T1 (en) 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
JPH08511420A (en) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド Body
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20040002117A1 (en) 1998-02-12 2004-01-01 Hogan Patrick G. Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (en) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
KR100940380B1 (en) 1999-01-15 2010-02-02 제넨테크, 인크. Polypeptide Variants with Altered Effector Function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1165766A2 (en) 1999-03-05 2002-01-02 Incyte Pharmaceuticals, Inc. Human secretory proteins
ES2571230T3 (en) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedure to control the activity of an immunofunctional molecule
US20030224379A1 (en) 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
EP1401281A4 (en) 2001-05-09 2004-12-29 Univ Yale Toll/interleukin-1 receptor adaptor protein (tirap)
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
CN102911987B (en) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 The adorned cell of genome
ATE493433T1 (en) 2002-09-11 2011-01-15 Genentech Inc NEW COMPOSITION AND METHOD FOR TREATING IMMUNE DISEASES
JP2006516089A (en) 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド Compositions and methods for tumor diagnosis and treatment
AU2003290432A1 (en) * 2002-12-26 2004-07-22 Asahi Kasei Pharma Corporation T cell activating gene
JP4869064B2 (en) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド High concentration antibody and protein preparation
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7622265B2 (en) 2005-02-22 2009-11-24 Genentech, Inc. Methods and compositions for modulating prostasin
EP1891107B1 (en) 2005-05-12 2011-07-06 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
WO2007124283A2 (en) 2006-04-13 2007-11-01 Zymogenetics, Inc. Tetramerizing polypeptides and methods of use
CA2648925A1 (en) 2006-04-13 2007-10-25 Zymogenetics, Inc. Tetramerizing polypeptides and methods of use
US20090318376A1 (en) 2006-06-15 2009-12-24 Korea Research Institute Of Bioscience And Biotechnology High Throughput Screening Method of Binding Inhibitor Between caspase3 and XIAP and Binding Inhibitor Screened Thereby
EP2057465A4 (en) 2006-08-09 2010-04-21 Homestead Clinical Corp Organ-specific proteins and methods of their use
CN101541834A (en) * 2006-10-06 2009-09-23 武田药品工业株式会社 Prophylactic or therapeutic agent for cancer
EP2185199A4 (en) * 2007-07-31 2010-09-08 Merck Sharp & Dohme Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
EP2279412B1 (en) 2008-04-09 2017-07-26 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
US20110236903A1 (en) 2008-12-04 2011-09-29 Mcclelland Michael Materials and methods for determining diagnosis and prognosis of prostate cancer
JP5725508B2 (en) 2009-03-25 2015-05-27 国立大学法人東北大学 LH type bispecific antibody
TW201132813A (en) 2010-03-03 2011-10-01 Koo Foundation Sun Yat Sen Cancer Ct Methods for classifying and treating breast cancers
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
WO2012129488A2 (en) 2011-03-23 2012-09-27 Virginia Commonwealth University Gene signatures associated with rejection or recurrence of cancer
EP2710147A1 (en) 2011-05-18 2014-03-26 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
WO2012178128A1 (en) 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
WO2013184912A2 (en) * 2012-06-06 2013-12-12 Oncomed Pharmaceuticals, Inc. Binding agents that modulate the hippo pathway and uses thereof
CN103073644B (en) 2012-12-31 2014-03-12 中国科学技术大学 Specific anti-mouse TIGIT monoclonal antibody and preparation method, identification and application thereof
MY183503A (en) 2013-07-16 2021-02-23 Genentech Inc Method of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
UA122395C2 (en) 2014-08-19 2020-11-10 Мерк Шарп Енд Доум Корп. ANTIBODY AGAINST TIGIT
PL3221346T3 (en) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
SG10202006538TA (en) 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit
EP3978929A1 (en) 2015-02-19 2022-04-06 Compugen Ltd. Pvrig polypeptides and methods of treatment
PT3653221T (en) 2015-02-19 2022-11-08 Compugen Ltd Anti-pvrig antibodies and methods of use
TWI715587B (en) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Tigit-binding agents and uses thereof
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
JO3620B1 (en) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers cancers
CA2997179A1 (en) 2015-09-02 2017-03-09 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
JP6764474B2 (en) 2015-09-25 2020-09-30 ジェネンテック， インコーポレイテッド Anti-TIGIT antibody and usage
RU2729379C1 (en) 2015-10-01 2020-08-06 Потенза Терапевтикс, Инк. Anti-tigit antigen-binding proteins and methods for use thereof
WO2018017864A2 (en) 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
PT3347379T (en) 2016-08-17 2020-02-18 Compugen Ltd Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof

Also Published As

Publication number Publication date
LT3295951T (en) 2020-09-25
PL3295951T3 (en) 2020-10-05
DK3258951T3 (en) 2020-04-06
IL254039B2 (en) 2023-12-01
JP7115856B2 (en) 2022-08-09
EP3653221B1 (en) 2022-08-03
HRP20200572T1 (en) 2020-08-21
IL254039A0 (en) 2017-10-31
CY1122970T1 (en) 2021-10-29
LT3653221T (en) 2022-11-10
CN107580500B (en) 2023-05-30
US20200148769A1 (en) 2020-05-14
HUE061084T2 (en) 2023-05-28
US20240101669A1 (en) 2024-03-28
KR102669294B1 (en) 2024-05-23
RU2732042C2 (en) 2020-09-10
CA2976926A1 (en) 2016-08-25
KR20170137067A (en) 2017-12-12
US20180244774A1 (en) 2018-08-30
AU2024202336A1 (en) 2024-05-16
DK3295951T3 (en) 2020-07-20
HUE049791T2 (en) 2020-10-28
PT3295951T (en) 2020-07-21
EP3258951A1 (en) 2017-12-27
DK3653221T3 (en) 2022-10-24
US20170029504A1 (en) 2017-02-02
HRP20221284T1 (en) 2022-12-23
EP3653221A1 (en) 2020-05-20
IL304117A (en) 2023-09-01
US9714289B2 (en) 2017-07-25
US10227408B2 (en) 2019-03-12
SI3295951T1 (en) 2020-10-30
SI3258951T1 (en) 2020-07-31
US10351625B2 (en) 2019-07-16
CN107580500A (en) 2018-01-12
ES2786651T3 (en) 2020-10-13
WO2016134333A1 (en) 2016-08-25
AU2020264349B2 (en) 2024-05-02
ES2806800T3 (en) 2021-02-18
EP3295951B1 (en) 2020-04-22
PL3258951T3 (en) 2020-07-27
CY1123259T1 (en) 2021-12-31
IL254039B1 (en) 2023-08-01
RU2017132214A (en) 2019-03-19
MX2017010667A (en) 2018-08-15
EP3258951B1 (en) 2020-01-29
PT3258951T (en) 2020-08-18
RU2017132214A3 (en) 2019-08-28
JP2018512443A (en) 2018-05-17
AU2016219835B2 (en) 2020-12-03
CN115350275A (en) 2022-11-18
LT3258951T (en) 2020-05-11
HRP20201066T1 (en) 2021-02-05
HK1247569A1 (en) 2018-09-28
WO2016134333A9 (en) 2017-02-02
AU2020264349A1 (en) 2020-12-03
RU2020128686A (en) 2020-10-13
US20170081408A1 (en) 2017-03-23
HUE049032T2 (en) 2020-08-28
US11795220B2 (en) 2023-10-24
PT3653221T (en) 2022-11-08
JP2022106783A (en) 2022-07-20
US20210188974A1 (en) 2021-06-24
EP3295951A1 (en) 2018-03-21
ES2929293T3 (en) 2022-11-28
EP4129320A1 (en) 2023-02-08
MX2020009461A (en) 2021-02-17
AU2016219835A1 (en) 2017-09-14
HK1247568A1 (en) 2018-09-28
PL3653221T3 (en) 2022-12-19
US11623955B2 (en) 2023-04-11
ZA201706323B (en) 2020-05-27
US20160244521A1 (en) 2016-08-25
US11220542B2 (en) 2022-01-11

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
HK1258058A1 (en) Anti-tigit antibodies and methods of use
HK1252858A1 (en) Anti-cll-1 antibodies and methods of use
HK1249445A1 (en) Anti-sortilin antibodies and methods of use thereof
HK1252698A1 (en) Anti-siglec-9 antibodies and methods of use thereof
IL259495A (en) Antibodies and methods of use thereof
HK1252696A1 (en) Anti-siglec-7 antibodies and methods of use thereof
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
IL270793A (en) Anti-htra1 antibodies and methods of use thereof
HK1258850A1 (en) Anti-tpbg antibodies and methods of use